Lung Transplantation in Autoimmune Diseases

Clinics in Chest Medicine

Volumn 31, Issue 3, 2010, Pages 589-603

  Lee, James C ^a   Ahya, Vivek N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoimmune diseases; Lung diseases; Lung transplantation

Indexed keywords

AZITHROMYCIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RAPAMYCIN;

ACUTE GRAFT REJECTION; ACUTE LUNG INJURY; ANTIBODY PRODUCTION; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; CHRONIC GRAFT REJECTION; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EXERCISE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTENSIVE CARE UNIT; KIDNEY FAILURE; LUNG BIOPSY; LUNG FUNCTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PATIENT SELECTION; PLASMAPHERESIS; PNEUMONIA; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; PULMONARY VASCULAR DISEASE; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; RISK ASSESSMENT; STOMACH FUNDOPLICATION; STOMACH PARESIS; SURGICAL TECHNIQUE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM;

EID: 77955400609     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2010.05.003     Document Type: Review

References (122)

1. Christie J.D., Edwards L.B., Aurora P., et al. The registry of the International Society For Heart And Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant 2009, 28(10):1031-1049.
2. Hardy J.D., Webb W.R., Dalton M.L., et al. Lung homotransplantation in man. JAMA 1963, 186:1065-1074.
3. Reitz B.A., Wallwork J.L., Hunt S.A., et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982, 306(10):557-564.
4. Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med 1986, 314(18):1140-1145.
5. Bhorade S.M., Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009, 6(1):47-53.
6. Egan T.M., Murray S., Bustami R.T., et al. Development of the new lung allocation system in the United States. Am J Transplant 2006, 6(5 Pt 2):1212-1227.
7. Lee J.C., Christie J.D. Primary graft dysfunction. Proc Am Thorac Soc 2009, 6(1):39-46.
8. de Perrot M., Bonser R.S., Dark J., et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant 2005, 24(10):1460-1467.
9. Barr M.L., Kawut S.M., Whelan T.P., et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipient-related risk factors and markers. J Heart Lung Transplant 2005, 24(10):1468-1482.
10. Daud S.A., Yusen R.D., Meyers B.F., et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007, 175(5):507-513.
11. Christie J.D., Kotloff R.M., Ahya V.N., et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005, 171(11):1312-1316.
12. Hopkins P.M., Aboyoun C.L., Chhajed P.N., et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 2002, 21(10):1062-1067.
13. Martinu T., Chen D.F., Palmer S.M. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc 2009, 6(1):54-65.
14. Stewart S., Fishbein M.C., Snell G.I., et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007, 26(12):1229-1242.
15. Belperio J.A., Weigt S.S., Fishbein M.C., et al. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009, 6(1):108-121.
16. Estenne M., Maurer J.R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002, 21(3):297-310.
17. Kugler C., Fischer S., Gottlieb J., et al. Health-related quality of life in two hundred-eighty lung transplant recipients. J Heart Lung Transplant 2005, 24(12):2262-2268.
18. Burton C.M., Carlsen J., Mortensen J., et al. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2007, 26(7):681-686.
19. Lama V.N., Murray S., Mumford J.A., et al. Prognostic value of bronchiolitis obliterans syndrome stage 0-p in single-lung transplant recipients. Am J Respir Crit Care Med 2005, 172(3):379-383.
20. Jackson C.H., Sharples L.D., McNeil K., et al. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities?. J Heart Lung Transplant 2002, 21(6):658-666.
21. Horvath E.P., doPico G.A., Barbee R.A., et al. Nitrogen dioxide-induced pulmonary disease: five new cases and a review of the literature. J Occup Med 1978, 20(2):103-110.
22. Kreiss K., Gomaa A., Kullman G., et al. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N Engl J Med 2002, 347(5):330-338.
23. Lai R.S., Chiang A.A., Wu M.T., et al. Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan. Lancet 1996, 348(9020):83-85.
24. Visscher D.W., Myers J.L. Bronchiolitis: the pathologist's perspective. Proc Am Thorac Soc 2006, 3(1):41-47.
25. Shilling R.A., Wilkes D.S. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am J Transplant 2009, 9(8):1714-1718.
26. Vanaudenaerde B.M., Meyts I., Vos R., et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008, 32(4):832-843.
27. Crosbie P.A., Woodhead M.A. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009, 33(1):171-181.
28. Williams T.J., Verleden G.M. Azithromycin: a plea for multicenter randomized studies in lung transplantation. Am J Respir Crit Care Med 2005, 172(6):657-659.
29. Iacono A.T., Johnson B.A., Grgurich W.F., et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006, 354(2):141-150.
30. Barshes N.R., DiBardino D.J., McKenzie E.D., et al. Combined lung and liver transplantation: the United States experience. Transplantation 2005, 80(9):1161-1167.
31. Levy R.D., Guerraty A.J., Yacoub M.H., et al. Prolonged survival after heart-lung transplantation in systemic lupus erythematosus. Chest 1993, 104(6):1903-1905.
32. Orens J.B., Estenne M., Arcasoy S., et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006, 25(7):745-755.
33. Choi J.K., Kearns J., Palevsky H.I., et al. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am J Respir Crit Care Med 1999, 160(3):1015-1018.
34. Gammie J.S., Pham S.M., Colson Y.L., et al. Influence of panel-reactive antibody on survival and rejection after lung transplantation. J Heart Lung Transplant 1997, 16(4):408-415.
35. Lau C.L., Palmer S.M., Posther K.E., et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000, 69(5):1520-1524.
36. Hadjiliadis D., Chaparro C., Reinsmoen N.L., et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005, 24(Suppl 7):S249-S254.
37. Shah A.S., Nwakanma L., Simpkins C., et al. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg 2008, 85(6):1919-1924.
38. Girnita A.L., McCurry K.R., Iacono A.T., et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004, 23(10):1135-1141.
39. Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008, 86(8):1019-1025.
40. Showkat A., Lo A., Shokouh-Amiri H., et al. Are autoimmune diseases or glomerulonephritis affecting the development of panel-reactive antibodies in candidates for renal transplantation?. Transplant Proc 2005, 37(2):645-647.
41. Sherer Y., Gorstein A., Fritzler M.J., et al. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004, 34(2):501-537.
42. Thervet E., Anglicheau D., Legendre C. Recent issues concerning renal transplantation in systemic lupus erythematosus patients. Nephrol Dial Transplant 2001, 16(1):12-14.
43. Prakash U.B. Respiratory complications in mixed connective tissue disease. Clin Chest Med 1998, 19(4):733-746. ix.
44. Gilchrist J.M. Overview of neuromuscular disorders affecting respiratory function. Semin Respir Crit Care Med 2002, 23(3):191-200.
45. Gonzalez Castro A., Suberviola Canas B., Quesada Suescun A., et al. Med Intensiva 2008, 32(2):65-70. [in Spanish].
46. Sager J.S., Kotloff R.M., Ahya V.N., et al. Association of clinical risk factors with functional status following lung transplantation. Am J Transplant 2006, 6(9):2191-2201.
47. Kadikar A., Maurer J., Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant 1997, 16(3):313-319.
48. Kawut S.M., O'Shea M.K., Bartels M.N., et al. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med 2005, 99(11):1431-1439.
49. Lederer D.J., Arcasoy S.M., Wilt J.S., et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174(6):659-664.
50. Tuppin M.P., Paratz J.D., Chang A.T., et al. Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant 2008, 27(7):729-734.
51. Impens A.J., Wangkaew S., Seibold J.R. The 6-minute walk test in scleroderma-how measuring everything measures nothing. Rheumatology (Oxford) 2008, 47(Suppl 5):v68-v69.
52. Benzo R., Kelley G.A., Recchi L., et al. Complications of lung resection and exercise capacity: a meta-analysis. Respir Med 2007, 101(8):1790-1797.
53. Levine S.M. A survey of clinical practice of lung transplantation in North America. Chest 2004, 125(4):1224-1238.
54. Gordon D., Inturrisi C.E., Greensmith J.E., et al. Perioperative pain management in the opioid-tolerant individual. J Pain 2008, 9(5):383-387.
55. King-Biggs M.B., Dunitz J.M., Park S.J., et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003, 75(9):1437-1443.
56. McAnally K.J., Valentine V.G., LaPlace S.G., et al. Effect of pre-transplantation prednisone on survival after lung transplantation. J Heart Lung Transplant 2006, 25(1):67-74.
57. Sheiner P.A., Mor E., Chodoff L., et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. Transplantation 1994, 57(7):1132-1133.
58. Saravanan V., Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006, 45(7):787-789.
59. Sawada T., Inokuma S., Sato T., et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009, 48(9):1069-1072.
60. Chikura B., Lane S., Dawson J.K. Clinical expression of leflunomide-induced pneumonitis. Rheumatology (Oxford) 2009, 48(9):1065-1068.
61. Champion L., Stern M., Israel-Biet D., et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006, 144(7):505-509.
62. Taki H., Kawagishi Y., Shinoda K., et al. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int 2009, 30(2):275-276.
63. Yegen H.A., Lederer D.J., Barr R.G., et al. Risk factors for venous thromboembolism after lung transplantation. Chest 2007, 132(2):547-553.
64. Izbicki G., Bairey O., Shitrit D., et al. Increased thromboembolic events after lung transplantation. Chest 2006, 129(2):412-416.
65. Schulman L.L., Anandarangam T., Leibowitz D.W., et al. Four-year prospective study of pulmonary venous thrombosis after lung transplantation. J Am Soc Echocardiogr 2001, 14(8):806-812.
66. Burgos P.I., Alarcon G.S. Thrombosis in systemic lupus erythematosus: risk and protection. Expert Rev Cardiovasc Ther 2009, 7(12):1541-1549.
67. Stone J.H., Amend W.J., Criswell L.A. Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 1999, 34(6):1040-1047.
68. Wagenknecht D.R., Becker D.G., LeFor W.M., et al. Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation 1999, 68(2):241-246.
69. Ducloux D., Pellet E., Fournier V., et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999, 67(1):90-93.
70. Morrissey P.E., Ramirez P.J., Gohh R.Y., et al. Management of thrombophilia in renal transplant patients. Am J Transplant 2002, 2(9):872-876.
71. Magro C.M., Pope-Harman A., Moh P., et al. Primary anti-phospholipid antibody syndrome caused by isolated anti-phosphatidylethanolamine antibodies presenting as cryptogenic fibrosing alveolitis with recurrent pulmonary hemorrhage after single-lung transplantation. J Heart Lung Transplant 2002, 21(11):1232-1236.
72. Covarrubias M., Ware L.B., Kawut S.M., et al. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007, 7(11):2573-2578.
73. Lee J.C.K.C., Hadjiliadis D., Aahya V.N., et al. Risk factors for early vs late primary graft dysfunction. Am J Respir Crit Care Med 2008, 177:A396. [abstract].
74. Webert K.E., Blajchman M.A. Transfusion-related acute lung injury. Transfus Med Rev 2003, 17(4):252-262.
75. Christie J.D., Kotloff R.M., Pochettino A., et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003, 124(4):1232-1241.
76. King R.C., Binns O.A., Rodriguez F., et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000, 69(6):1681-1685.
77. Thabut G., Vinatier I., Stern J.B., et al. Primary graft failure following lung transplantation: predictive factors of mortality. Chest 2002, 121(6):1876-1882.
78. Lee J.C., Kuntz C., Kawut S.M., et al. Clinical risk factors for the development of primary graft dysfunction. J Heart Lung Transplant 2008, 27(2 Suppl 1):S67-S68.
79. Kawut S.M., Okun J., Shimbo D., et al. Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation. Chest 2009, 136(1):237-244.
80. Forbes A., Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl 3):iii36-iii39.
81. Savarino E., Bazzica M., Zentilin P., et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009, 179(5):408-413.
82. Napierkowski J., Wong R.K. Extraesophageal manifestations of GERD. Am J Med Sci 2003, 326(5):285-299.
83. Sweet M.P., Patti M.G., Hoopes C., et al. Gastro-oesophageal reflux and aspiration in patients with advanced lung disease. Thorax 2009, 64(2):167-173.
84. Parsons JP., Mastronarde JG. Gastroesophageal reflux disease and asthma. Curr Opin Pulm Med 2010, 16(1):60-63.
85. Troshinsky M.B., Kane G.C., Varga J., et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994, 121(1):6-10.
86. D'Ovidio F., Singer L.G., Hadjiliadis D., et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg 2005, 80(4):1254-1260.
87. Akindipe O.A., Faul J.L., Vierra M.A., et al. The surgical management of severe gastroparesis in heart/lung transplant recipients. Chest 2000, 117(3):907-910.
88. Young L.R., Hadjiliadis D., Davis R.D., et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003, 124(5):1689-1693.
89. D'Ovidio F., Mura M., Ridsdale R., et al. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant 2006, 6(8):1930-1938.
90. Cossio M., Menon Y., Wilson W., et al. Life-threatening complications of systemic sclerosis. Crit Care Clin 2002, 18(4):819-839.
91. Palmer S.M., Miralles A.P., Howell D.N., et al. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest 2000, 118(4):1214-1217.
92. Hadjiliadis D., Duane Davis R., Steele M.P., et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant 2003, 17(4):363-368.
93. D'Ovidio F., Mura M., Tsang M., et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005, 129(5):1144-1152.
94. Blondeau K., Mertens V., Vanaudenaerde B.A., et al. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J 2008, 31(4):707-713.
95. D'Ovidio F., Keshavjee S. Gastroesophageal reflux and lung transplantation. Dis Esophagus 2006, 19(5):315-320.
96. Davis R.D., Lau C.L., Eubanks S., et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003, 125(3):533-542.
97. Cantu E., Appel J.Z., Hartwig M.G., et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004, 78(4):1142-1151. [discussion: 1142-51].
98. Robertson A.G., Shenfine J., Ward C., et al. A call for standardization of antireflux surgery in the lung transplantation population. Transplantation 2009, 87(8):1112-1114.
99. Robertson A.G., Griffin S.M., Murphy D.M., et al. Targeting allograft injury and inflammation in the management of post-lung transplant bronchiolitis obliterans syndrome. Am J Transplant 2009, 9(6):1272-1278.
100. Linden P.A., Gilbert R.J., Yeap B.Y., et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg 2006, 131(2):438-446.
101. Dallemagne B., Weerts J., Markiewicz S., et al. Clinical results of laparoscopic fundoplication at ten years after surgery. Surg Endosc 2006, 20(1):159-165.
102. Kelly J.J., Watson D.I., Chin K.F., et al. Laparoscopic Nissen fundoplication: clinical outcomes at 10 years. J Am Coll Surg 2007, 205(4):570-575.
103. Eckardt A.J., Pinnow G., Pohl H., et al. Antireflux 'barriers': problems with patient recruitment for a new endoscopic antireflux procedure. Eur J Gastroenterol Hepatol 2009, 21(10):1110-1118.
104. Burton P.R., Button B., Brown W., et al. Medium-term outcome of fundoplication after lung transplantation. Dis Esophagus 2009, 22(8):642-648.
105. Gasper W.J., Sweet M.P., Hoopes C., et al. Antireflux surgery for patients with end-stage lung disease before and after lung transplantation. Surg Endosc 2008, 22(2):495-500.
106. Limpert P.A., Naunheim K.S. Partial versus complete fundoplication: is there a correct answer?. Surg Clin North Am 2005, 85(3):399-410.
107. Gasper W.J., Sweet M.P., Golden J.A., et al. Lung transplantation in patients with connective tissue disorders and esophageal dysmotility. Dis Esophagus 2008, 21(7):650-655.
108. Christie J.D., Sager J.S., Kimmel S.E., et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005, 127(1):161-165.
109. Hafkin J., Blumberg E. Infections in lung transplantation: new insights. Curr Opin Organ Transplant 2009, 14(5):483-487.
110. Barton T.D., Blumberg E.A. Viral pneumonias other than cytomegalovirus in transplant recipients. Clin Chest Med 2005, 26(4):707-720. viii.
111. Remund K.F., Best M., Egan J.J. Infections relevant to lung transplantation. Proc Am Thorac Soc 2009, 6(1):94-100.
112. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000, 23(2):101-113.
113. Loren A.W., Tsai D.E. Post-transplant lymphoproliferative disorder. Clin Chest Med 2005, 26(4):631-645. vii.
114. Lyu D.M., Zamora M.R. Medical complications of lung transplantation. Proc Am Thorac Soc 2009, 6(1):101-107.
115. Roithmaier S., Haydon A.M., Loi S., et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 2007, 26(8):845-849.
116. Levine S.M., Anzueto A., Peters J.I., et al. Single lung transplantation in patients with systemic disease. Chest 1994, 105(3):837-841.
117. Pigula F.A., Griffith B.P., Zenati M.A., et al. Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 1997, 64(6):1630-1634.
118. Rosas V., Conte J.V., Yang S.C., et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000, 5(3):38-43.
119. Kubo M., Vensak J., Dauber J., et al. Lung transplantation in patients with scleroderma. J Heart Lung Transplant 2001, 20(2):174-175.
120. Massad M.G., Powell C.R., Kpodonu J., et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 2005, 29(11):1510-1515.
121. Schachna L., Medsger T.A., Dauber J.H., et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006, 54(12):3954-3961.
122. Shitrit D., Amital A., Peled N., et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant 2009, 23(2):178-183.